ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between February 22 and August 22, 2026 — up from exactly one in the prior six-month window. That is a 1,900% increase, period over period. The surge is not a statistical quirk driven by one mega-deal or a single buyer on a spree. It reflects a structural repricing of ADC assets across the industry, driven by clinical validation in solid tumors beyond HER2, Big Pharma's desperation to fill late-stage oncology gaps, and a licensing market that has finally recalibrated after the post-Enhertu hangover of 2024–2025.

The Data — ADC Deal Activity, Period over Period

The prior period's single deal was an outlier of inactivity, not normalcy — but even against the trailing 12-month average from 2024–2025, the current pace represents a step-change. ADC licensing in 2026 is running at roughly 3–4x the annualized rate we tracked across 2024. The market has shifted from cautious to competitive in under two quarters.

What's Driving the Trend

Clinical validation beyond Enhertu's shadow. For 18 months after Daiichi Sankyo's transformative AstraZeneca partnership, the ADC field suffered from a paradox: everyone wanted ADCs, but most assets were benchmarked against trastuzumab deruxtecan — an impossible standard that froze deals. That logjam broke in late 2025 and early 2026 as multiple next-generation ADC platforms demonstrated differentiated clinical data. Novel payloads (topoisomerase I inhibitor alternatives, immunostimulatory payloads), site-specific conjugation chemistries, and bystander-effect-optimized linkers have expanded the design space enough that buyers can now underwrite assets on their own merits rather than asking "is this better than T-DXd?"

Big Pharma pipeline anxiety. The oncology patent cliff is no longer a forecast — it is here. Several blockbuster checkpoint inhibitors face biosimilar competition by 2028–2030, and the replacement pipeline is thin. ADCs represent the most de-risked next-generation modality in solid tumors: the mechanism is validated, the regulatory pathway is understood, and the manufacturing complexity, while real, is no longer a gating risk for experienced CMOs. GSK's $185M upfront to Hansoh and Novartis's dual-deal structure with Myricx Bio (total deal values of $1.5B and $1.1B) are not exploratory bets. They are pipeline-building transactions executed with urgency.

Capital markets reopening for biotech. The IPO and follow-on window that cracked open in Q4 2025 gave ADC-focused biotechs alternatives to licensing. Counterintuitively, this accelerated deal activity: companies with funded runways negotiated from strength, demanding higher upfronts and more favorable milestones. Buyers, recognizing that the best assets would go public rather than license on weak terms, moved faster and paid more. The result is a seller's market that is rewarding clinical-stage ADC companies with significant leverage — a dynamic visible in the deal structures we are tracking on our Deal Benchmarks platform.

Notable Deals

Hansoh–GSK ($185M upfront / $1.7B TDV). This is the marquee transaction of the cycle. GSK paid a disclosed $185M upfront — approximately 10.9% of total deal value — which sits at the higher end of the upfront-to-TDV ratio we track for oncology licensing deals (median is roughly 8–9% based on Deal Benchmarks data). GSK's willingness to pay above-median upfront signals high conviction in Hansoh's asset and, critically, competitive pressure from other bidders. Hansoh's growing out-licensing franchise, built on a differentiated ADC platform, gives it the kind of repeat-deal credibility that commands premium terms.

Myricx Bio–Novartis (two deals, $1.5B and $1.1B TDV). Novartis executed two separate agreements with Myricx in a single day — a structure that strongly suggests a platform-level commitment rather than an asset-by-asset license. The combined $2.6B in total deal value without disclosed upfronts points toward milestone-heavy structures, likely with option-based triggers tied to clinical proof-of-concept. This is Novartis playing the long game: locking up optionality across multiple targets while keeping upfront capital exposure contained. For BD teams at other biotechs, this deal pair sets a precedent for platform licensing structures that preserve optionality for both parties.

Biocytogen–Whitehawk ($500M TDV). Whitehawk's deal with Biocytogen is notable for the buyer profile. This is not a top-10 pharma company — it is a smaller, more specialized acquirer making a targeted bet. The entry of mid-cap and specialty pharma buyers into the ADC licensing market is a meaningful signal. It expands the buyer universe and creates competitive dynamics on assets that historically would have attracted only 3–4 serious bidders. More buyers means better terms for licensors.

What This Means for BD Teams Right Now

If you are selling: This is unambiguously a seller's market for clinical-stage ADC assets with differentiated mechanisms. Upfront-to-TDV ratios are compressing upward, meaning buyers are paying more cash at signing relative to total headline value. The data supports aggressive term negotiation. If your ADC has Phase I data in a solid tumor indication with a novel payload or target, you should be running a competitive process with at least 4–5 potential partners. Running a bilateral negotiation in this environment is leaving money on the table.

If you are buying: Speed matters more than precision right now. The window to acquire high-quality ADC assets at 2024 pricing is closed. Waiting for additional clinical data before engaging will cost you — either in higher upfronts or in losing the asset entirely to a competitor willing to underwrite risk earlier. The smart play is structured optionality: option-based deals with lower upfronts but clearly defined decision gates, similar to the Novartis–Myricx architecture. This lets you secure access to platforms without overcommitting capital before clinical inflection points.

Deal structure trends: We are seeing three structural shifts in ADC licensing in 2026. First, platform deals (multi-target licenses) are gaining share versus single-asset deals — buyers want breadth, not just depth. Second, upfront payments are rising as a percentage of TDV, reflecting seller leverage. Third, co-development and co-commercialization provisions are appearing more frequently in deals with larger biotechs that have the infrastructure to participate post-Phase II. Use the Ambrosia calculator to model how these structural shifts affect the economics of your next transaction.

Benchmark your deal against current market rates. ADC deal terms are moving fast — what was market-rate in Q1 2026 is already below market in Q3. Use the Ambrosia calculator to stress-test your upfront, milestones, and royalty structure against the latest comparable transactions before you sit down at the table.